Study #2021-0660
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
MD Anderson Study Status
Enrolling
Treatment Agent
Description
The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer
Study phase:
Phase II
Physician name:
Aaron Shafer
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.